![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
12 Weeks of Daclatasvir in Combination With Sofosbuvir
for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by Black Race
|
|
|
Reported by Jules Levin
IDSA 2015 Oct 7-11 San Diego, CA
D Fishbein,1 A Mills,2 Y Zhao,3 S Noviello,3 P Ackerman41MedStar Health Research Institute, Washington DC, DC, USA; 2Southern California Men's Medical Group, Los Angeles, CA, USA; 3Bristol-Myers Squibb, Princeton, NJ, USA; 4Bristol-Myers Squibb, Wallingford, CT, USA.
![IDSA1.gif](../images/101415/101415-2/IDSA1.gif)
![IDSA2.gif](../images/101415/101415-2/IDSA2.gif)
![IDSA3.gif](../images/101415/101415-2/IDSA3.gif)
![IDSA4.gif](../images/101415/101415-2/IDSA4.gif)
![IDSA5.gif](../images/101415/101415-2/IDSA5.gif)
![IDSA6.gif](../images/101415/101415-2/IDSA6.gif)
![IDSA7.gif](../images/101415/101415-2/IDSA7.gif)
![IDSA8.gif](../images/101415/101415-2/IDSA8.gif)
![IDSA9.gif](../images/101415/101415-2/IDSA9.gif)
![IDSA10.gif](../images/101415/101415-2/IDSA10.gif)
![IDSA11.gif](../images/101415/101415-2/IDSA11.gif)
![IDSA12.gif](../images/101415/101415-2/IDSA12.gif)
![IDSA13.gif](../images/101415/101415-2/IDSA13.gif)
![IDSA14.gif](../images/101415/101415-2/IDSA14.gif)
![IDSA15.gif](../images/101415/101415-2/IDSA15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|